1,799
Views
5
CrossRef citations to date
0
Altmetric
Editorial

How to control recurrent angioedema using monoclonal antibody therapies?

&
Pages 1-4 | Received 19 Aug 2019, Accepted 08 Nov 2019, Published online: 14 Nov 2019
 

Declaration of interest

M Maurer recently was a speaker and advisor for, and has received research funding from, Allakos, Alnylam, Aralez, AstraZeneca, Biocryst, Blueprint, CSL Behring, FAES, Genentech, Kalvista, Menarini, Novartis, Leo Pharma, Moxie, MSD, Pharming, Pharvaris, Roche, Sanofi, Shire/Takeda, UCB, and Uriach.

M Magerl was recently was a Speaker and Advisor for BioCryst, CSL Behring, KalVista, Novartis, Shire, and Pharming.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer Disclosures

The peer reviewers have nothing to disclose.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.